Activated Jak2-Stat5 signaling can be readily targeted by the current Jak2-inhibitors that have been developed for myeloproliferative disorders (MPDs) and hematological malignancies, which will be reviewed here. The gene discussed is JAK2; the disease is hematologic disorder.